BrainStorm Cell Therapeutics Inc.'s Adult Stem Cell Approach More Relevant Than Embryonic Stem Cell Therapies
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that based on studies conducted to date, the Company’s adult stem cell therapies provide a safer approach at curing and treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells. In addition to the well-known ethical/religious concerns associated with embryonic stem cell therapies, experts are greatly concerned with the risk of the development of teratomas (or cancer) in patients as a result of the usage of embryonic stem cells. BrainStorm Cell Therapeutics is confident that its approach to stem cell treatments, using adult stem cells, eliminates this additional risk factor that embryonic stem cell treatments face. The Company expects that this will enable it to commercialize its products more quickly than its competitors, which will allow patients to benefit from its technologies and therapies more promptly.